The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests «we are finally poised to
deliver curative therapies to cancer patients,» researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.